Study of ARO-APOC3 in Adults With Mixed Dyslipidemia
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Participants who have met all protocol eligibility criteria will be randomly assigned to
treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluted for safety
and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet
throughout the study, as recommended by the Investigator in accordance with local standard of
care. After week 48, participants will be eligible and invited to consent and continue in an
open-label extension study. All placebo participants who opt to continue will switch to
active drug (ARO-APOC3) during the extension study.